Edistride Unione Europea - italiano - EMA (European Medicines Agency)

edistride

astrazeneca ab - dapagliflozin propanediolo monoidrato - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - farmaci usati nel diabete - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. in aggiunta ad altri medicinali per il trattamento del diabete di tipo 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 e 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

OMEGA 3 STRIDES ARCOLAB INTERNATIONAL Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

omega 3 strides arcolab international

strides arcolab international ltd - omega-3-trigliceridi inclusi altri esteri e acidi - omega-3-trigliceridi inclusi altri esteri e acidi

DUTASTERIDE STRIDES Italia - italiano - AIFA (Agenzia Italiana del Farmaco)

dutasteride strides

strides pharma(cyprus)ltd - dutasteride - dutasteride

STRIDESMOOTH+ MICROCATHETER Italia - italiano - Ministero della Salute

stridesmooth+ microcatheter

asahi intecc co., ltd - dispositivi per angiografia ed emodinamica - accessori altri

STRIDE MICROCATETERE Italia - italiano - Ministero della Salute

stride microcatetere

asahi intecc co., ltd - cateteri e microcateteri per embolizzazione periferica

Kauliv Unione Europea - italiano - EMA (European Medicines Agency)

kauliv

strides pharma (cyprus) limited - teriparatide - osteoporosis; osteoporosis, postmenopausal - omeostasi del calcio - kauliv is indicated in adults. treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5. in postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.